Which acute kidney injury patient is most likely to have hydronephrosis on renal ultrasound: a 19‑year‑old female with Escherichia coli O157:H7–associated thrombotic thrombocytopenic purpura; a 57‑year‑old male bartender with gonococcal sepsis and purpura fulminans; a 58‑year‑old woman receiving chemotherapy and radiation for advanced cervical cancer; a 75‑year‑old man with autosomal dominant polycystic kidney disease; or an elderly nursing‑home resident woman with pyelonephritis and sepsis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydronephrosis Risk in Acute Kidney Injury Patients

The 58-year-old woman undergoing chemotherapy and radiation for advanced cervical cancer is most likely to have hydronephrosis on ultrasound evaluation.

Rationale for Advanced Cervical Cancer

Cervical cancer with chemoradiation therapy creates the highest risk for hydronephrosis through multiple mechanisms:

  • Malignant obstruction from tumor compression of the ureters is a well-established cause of hydronephrosis, particularly in advanced cervical cancer 1, 2.

  • Radiation-induced hydronephrosis (RIH) occurs in approximately 7.2% of kidneys at 5 years post-treatment, with an overall incidence of 15.8% for new hydronephrosis during follow-up after chemoradiation 3.

  • The combination of external beam radiation with concurrent cisplatin and brachytherapy specifically increases risk, with Point A dose, bladder D2.0cc, and high-risk clinical target volume all independently associated with hydronephrosis development 3.

  • Hydronephrosis occurs in 12-23% of cervical cancer patients overall, with higher rates in those receiving radiotherapy (43% versus 25% in non-radiated patients) 4, 5, 6.

  • Both direct tumor invasion and treatment-related ureteral stenosis contribute to obstruction, making this a dual-mechanism risk 3.

Why Other Options Are Less Likely

E. coli O157:H7 with TTP (19-year-old female)

  • Thrombotic thrombocytopenic purpura causes intrarenal microvascular thrombosis, not obstructive uropathy 1.
  • This represents intrinsic renal disease (acute tubular necrosis pattern), which does not produce hydronephrosis 1.
  • Ultrasound would show normal-sized kidneys without collecting system dilation 1.

Gonococcal Sepsis with Purpura Fulminans (57-year-old male)

  • Sepsis-induced AKI is prerenal or intrinsic (acute tubular necrosis), not obstructive 1.
  • Obstructive uropathy is found in only about 1% of ICU patients with acute renal failure 1.
  • Purpura fulminans indicates disseminated intravascular coagulation, causing intrarenal injury rather than obstruction 1.

Autosomal Dominant Polycystic Kidney Disease (75-year-old male)

  • ADPKD causes multiple renal cysts, not hydronephrosis 1.
  • While cysts can mimic hydronephrosis on ultrasound, they represent a distinct pathology without collecting system obstruction 1.
  • Chronic kidney disease from ADPKD would show small echogenic kidneys if causing renal failure, not acute obstruction 1.

Pyelonephritis with Sepsis (elderly nursing home resident)

  • Pyelonephritis alone does not typically cause hydronephrosis unless complicated by obstruction 1.
  • While 33% of complicated urinary tract infections show sonographic abnormalities, these are usually parenchymal changes rather than hydronephrosis 1.
  • Pyonephrosis (infected hydronephrosis) requires pre-existing obstruction as the primary pathology 2.

Clinical Implications

The cervical cancer patient requires urgent evaluation because:

  • Bilateral hydronephrosis with elevated creatinine is a medical emergency requiring immediate decompression 7, 2.
  • Progressive dilation leads to permanent nephron loss if not corrected 1, 8.
  • Ultrasound has >90% sensitivity for detecting hydronephrosis and can guide intervention 1, 7.

Key Pitfalls to Avoid

  • Do not delay imaging in cervical cancer patients with AKI, as both tumor progression and radiation effects can cause obstruction 3, 5.
  • Hydronephrosis in cervical cancer is associated with significantly worse survival (hazard ratios 1.47-4.69), making early detection critical 6.
  • Approximately 20% of cervical cancer patients have persistent hydronephrosis after definitive treatment, requiring ongoing surveillance 3.
  • Silent (asymptomatic) hydronephrosis occurs, so imaging should not be withheld based on absence of flank pain alone 4, 9.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes and Considerations of Hydronephrosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Effect of hydronephrosis on survival in advanced stage cervical cancer.

Asian Pacific journal of cancer prevention : APJCP, 2015

Research

Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015

Guideline

Diagnostic Approach and Management of Hydronephrosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Right Hydronephrosis with Thinning of Renal Parenchyma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.